{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T15:11:06Z","timestamp":1648566666755},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1998,8,1]],"date-time":"1998-08-01T00:00:00Z","timestamp":901929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"published-print":{"date-parts":[[1998,8]]},"DOI":"10.1007\/bf03339790","type":"journal-article","created":{"date-parts":[[2014,1,17]],"date-time":"2014-01-17T02:47:39Z","timestamp":1389926859000},"page":"284-294","source":"Crossref","is-referenced-by-count":0,"title":["Bisphosphonates and osteoporosis treatment in Italy"],"prefix":"10.1007","volume":"10","author":[{"given":"C.","family":"Gennari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Y.","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,7]]},"reference":[{"key":"BF03339790_CR1","first-page":"3","volume-title":"Primer on the metabolic bone disease and disorders in mineral metabolism","author":"R Baron","year":"1993","unstructured":"Baron R.: Anatomy and ultrastructure of bone. In: Favus M.J. (Ed.), Primer on the metabolic bone disease and disorders in mineral metabolism. Raven Press, New York, 1993, pp. 3\u20139."},{"key":"BF03339790_CR2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jcb.240550303","volume":"55","author":"AM Parfitt","year":"1994","unstructured":"Parfitt A.M.: Osteonal and hemiosteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone. J. Cell. Biochem. 55: 273\u2013286, 1994.","journal-title":"J. Cell. Biochem."},{"key":"BF03339790_CR3","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0002-9343(93)90218-E","volume":"94","author":"Consensus Development Conference","year":"1993","unstructured":"Consensus Development Conference: Diagnosis, prevention and treatment of osteoporosis. Am. J. Med. 94: 646\u2013650, 1993.","journal-title":"Am. J. Med."},{"key":"BF03339790_CR4","first-page":"291","volume-title":"Osteoporosis \u201996","author":"C Christiansen","year":"1996","unstructured":"Christiansen C.: Bisphosphonates. In: Papapoulos S.E., Lips P., Pols H.A.P., Johnston C.C., Delmas P.D. (Eds.), Osteoporosis \u201996. Elsevier, Amsterdam, 1996, pp. 291\u2013298."},{"key":"BF03339790_CR5","first-page":"251","volume-title":"Osteoporosis \u201996","author":"R Lindsay","year":"1996","unstructured":"Lindsay R.: Estrogens and osteoporosis: clinical. In: Papapoulos S.E., Lips P., Pols H.A.P., Johnston C.C., Delmas P.D. (Eds.), Osteoporosis \u201996. Elsevier, Amsterdam, 1996, pp. 251\u2013256."},{"key":"BF03339790_CR6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0221-8747(81)90044-8","volume":"4\/5","author":"H Fleisch","year":"1981","unstructured":"Fleisch H.: Diphosphonates: history and mechanisms of action. Metab. Bone Dis. 4\/5: 279\u2013299, 1981.","journal-title":"Metab. Bone Dis."},{"key":"BF03339790_CR7","volume-title":"Bisphosphonates in bone disease. From the laboratory to the patient","author":"H Fleisch","year":"1995","unstructured":"Fleisch H.: Bisphosphonates in bone disease. From the laboratory to the patient. Stampfli Co. Ltd., Berne, 1995."},{"issue":"Suppl.3","key":"BF03339790_CR8","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1007\/BF01623001","volume":"3","author":"GA Rodan","year":"1993","unstructured":"Rodan G.A., Seedor J.G., Balena R.: Preclinical pharmacology of alendronate. Osteoporos. Int. 3 (Suppl. 3): S7\u2013S12, 1993.","journal-title":"Osteoporos. Int."},{"key":"BF03339790_CR9","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/bmj.294.6579.1048","volume":"294","author":"DA Heath","year":"1987","unstructured":"Heath D.A.: Treating Paget\u2019s disease. BMJ 294: 1048\u20131050, 1987.","journal-title":"BMJ"},{"key":"BF03339790_CR10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/jbmr.5650050510","volume":"5","author":"DP O\u2019Doherty","year":"1990","unstructured":"O\u2019Doherty D.P., Bickerstaff D.R., McCloskey E.V., Hamdy N.A.T., Beneton M.N.C., Harris S., Mian M., Kanis J.A.: Treatment of Paget\u2019s disease of bone with aminohydroxybutylidene bisphosphonate. J. Bone Miner. Res. 5: 483\u2013491, 1990.","journal-title":"J. Bone Miner. Res."},{"key":"BF03339790_CR11","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/jbmr.5650040617","volume":"4","author":"JJ Body","year":"1989","unstructured":"Body J.J., Magritte A., Seraj F., Sculier J.P., Borkowsi A.: Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between 3-day treatment and single 24-hour infusions. J. Bone Miner. Res. 4: 923\u2013928, 1989.","journal-title":"J. Bone Miner. Res."},{"issue":"S2A","key":"BF03339790_CR12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0002-9343(87)90487-6","volume":"82","author":"C Hasling","year":"1987","unstructured":"Hasling C., Charles P., Mosekilde L.: Etidronate disodium in the management of malignancy-related hypercalcemia. Am. J. Med. 82(S2A): 51\u201354, 1987.","journal-title":"Am. J. Med."},{"key":"BF03339790_CR13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0169-6009(92)90810-Z","volume":"18","author":"E Zysset","year":"1992","unstructured":"Zysset E., Ammann P., Jenzer A., Gertz B.J., Portmann L., Rizzoli R., Jaquet-Mueller F., Pryortillotson S., Bonjour J.P., Burkhardt P.: Comparison of rapid (2-h) versus slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy. Bone Miner. 18: 237\u2013249, 1992.","journal-title":"Bone Miner."},{"key":"BF03339790_CR14","first-page":"265","volume":"82","author":"HG Bone","year":"1997","unstructured":"Bone H.G., Downs R.W. Jr, Tucci J.R., Harris S.T., Weinstein R.S., Licata A.A., McClung M.R., Kimmel D.B., Gertz B.J., Hale E., Polvino W.J., for the Alendronate Elderly Osteoporosis Study Centers: Dose-response relationships for alendronate treatment in osteoporotic elderly women. J. Clin. Endocrinol. Metab. 82: 265\u2013274, 1997.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03339790_CR15","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","volume":"100","author":"PM Chavassieux","year":"1997","unstructured":"Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J.: Histomorphometric assessment of the longterm effects of alendronate on bone quality and remodeling in patients with osteoporosis. J. Clin. Invest. 100: 1475\u20131480, 1997.","journal-title":"J. Clin. Invest."},{"key":"BF03339790_CR16","first-page":"1693","volume":"79","author":"P Garnero","year":"1994","unstructured":"Garnero P., Shih W.J., Ginetys E., Karpf D.B., Delmas P.D.: Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 79: 1693\u20131700, 1994.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03339790_CR17","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1210\/jcem.82.9.4193","volume":"82","author":"P Bettica","year":"1997","unstructured":"Bettica P., Bevilacqua M., Vago T., Masino M., Norbiato G.: Short-term variations in type I collagen telopeptides excretion: cyclical etidronate and alendronate effects compared. J. Clin. Endocrinol. Metab. 82: 3034\u20133039, 1997.","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BF03339790_CR18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","volume":"99","author":"CHI Chesnut","year":"1995","unstructured":"Chesnut C.H.I., McClung M.R., Ensrud K.E., Bell N.H., Genant H.K., Harris S.T., Singer F.R., Stock J.L., Yood R.A., Delmas P.D., Kher U., Pryor-Tillotson S., Santora A.C.: Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am. J. Med. 99: 144\u2013152, 1995.","journal-title":"Am. J. Med."},{"key":"BF03339790_CR19","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","volume":"338","author":"DJ Hosking","year":"1998","unstructured":"Hosking D.J., Chilvers C.E.D., Christiansen C., Ravn P., Wasnich R.D., Ross P., McClung M.R., Balske A., Thompson D.E., Daley M., Yates A.J.: Early postmenopausal intervention cohort study group: Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N. Engl. J. Med. 338: 485\u2013492, 1998.","journal-title":"N. Engl. J. Med."},{"key":"BF03339790_CR20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S8756-3282(95)00262-6","volume":"17","author":"S Adami","year":"1995","unstructured":"Adami S., Passeri M., Ortolani S., Broggini M., Carratelli L., Caruso I., Gandolini G., Gnessi L., Laurenzi M., Lombardi A., Norbiato G., Pryor-Tillotson S., Reda C., Romanini L., Subrizi D., Wei L., Yates A.J.: Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 17: 383\u2013390, 1995.","journal-title":"Bone"},{"key":"BF03339790_CR21","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., Rodriguez-Portales J., Downs R.W., Dequeker J., Favus M., Seeman E., Recker R.R., Capizzi T., Santora A.C., Lombardi A., Shah R.V., Hirsch L.J., Karpf D.B., for the Alendronate Phase III Osteoporosis treatment Study Group: Effect of oral alendronate on bone mineral density and the incidence of fracture in postmenopausal osteoporosis. N. Engl. J. Med. 333: 1437\u20131443, 1995.","journal-title":"N. Engl. J. Med."},{"key":"BF03339790_CR22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0002-9343(96)00282-3","volume":"101","author":"JR Tucci","year":"1996","unstructured":"Tucci J.R., Tonino R.P., Emkey R.D., Peverly C.A., Kher U., Santora A.C. II, for the U.S. Alendronate Phase III Osteoporosis treatment Study Group: Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am. J. Med. 101: 488\u2013501, 1996.","journal-title":"Am. J. Med."},{"key":"BF03339790_CR23","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., Ensrud K.E., for the Fracture Intervention trial Research Group: Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 1535\u20131541, 1996.","journal-title":"Lancet"},{"key":"BF03339790_CR24","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1001\/archinte.1997.00440430099012","volume":"157","author":"KE Ensrud","year":"1997","unstructured":"Ensrud K.E., Black D.M., Palermo L., Bauer D.C., Barret-Connor E., Quandt S.A., Thompson D.E., Karpf D.B.: Treatment with alendronate prevents fractures in women at highest risk: Results from the Fracture Intervention trial. Arch. Intern. Med. 157: 2617\u20132624, 1997.","journal-title":"Arch. Intern. Med."},{"key":"BF03339790_CR25","first-page":"1889","volume":"90","author":"G Maconi","year":"1995","unstructured":"Maconi G., Bianchi Porro G.: Multiple ulcerative esophagitis caused by alendronate. Am. J. Gastroenterol. 90: 1889\u20131890, 1995.","journal-title":"Am. J. Gastroenterol."},{"key":"BF03339790_CR26","first-page":"1282","volume":"91","author":"MF Abdelmalek","year":"1996","unstructured":"Abdelmalek M.F., Douglas D.D.: Alendronate-induced ulcerative esophagitis. Am. J. Gastroenterol. 91: 1282\u20131283, 1996.","journal-title":"Am. J. Gastroenterol."},{"key":"BF03339790_CR27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0016-5107(97)70018-X","volume":"46","author":"RB Cameron","year":"1997","unstructured":"Cameron R.B.: Esophagitis dissecans superficialis and alendronate: case report. Gastrointest. Endosc. 46: 562\u2013563, 1997.","journal-title":"Gastrointest. Endosc."},{"key":"BF03339790_CR28","first-page":"704","volume":"92","author":"RE Colina","year":"1997","unstructured":"Colina R.E., Smith M., Kikendall J.W., Wong R.K.H.: A new probable increasing cause of esophageal ulceration: Alendronate. Am. J. Gastroenterol. 92: 704\u2013706, 1997.","journal-title":"Am. J. Gastroenterol."},{"key":"BF03339790_CR29","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","volume":"335","author":"PC Groen de","year":"1996","unstructured":"de Groen P.C., Lubbe D.F., Hirsch L.J., Daifotis A., Stephenson W., Freedholm D., Pryor-Tillotson S., Seleznick M.J., Pinkas H., Wang K.K.: Esophagitis associated with the use of alendronate. N. Engl. J. Med. 335: 1016\u20131021, 1996.","journal-title":"N. Engl. J. Med."},{"key":"BF03339790_CR30","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0002-9343(97)89446-6","volume":"102","author":"RJ Levine","year":"1997","unstructured":"Levine R.J., Nelson D.: Esophageal stricture associated with alendronate therapy. Am. J. Med. 102: 489\u2013491, 1997.","journal-title":"Am. J. Med."},{"key":"BF03339790_CR31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/(SICI)1099-1557(199707)6:4<235::AID-PDS293>3.0.CO;2-3","volume":"6","author":"F Mackay","year":"1997","unstructured":"Mackay F., Wilton L.V., Pearce G., Freemantle S., Mann R.D.: Alendronate and oesophageal reactions. Pharmacoepidemiology and Drug Safety 6: 20, 1997.","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"BF03339790_CR32","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(05)64955-0","volume":"348","author":"G Naylor","year":"1996","unstructured":"Naylor G., Davies M.H.: Oesophageal stricture associated with alendronic acid. Lancet 348: 1030\u20131031, 1996.","journal-title":"Lancet"},{"key":"BF03339790_CR33","first-page":"181","volume":"124","author":"E Pizzani","year":"1997","unstructured":"Pizzani E., Valenzuela G.: Esophagitis associated with alendronate sodium. VMQ 124: 181\u2013182, 1997.","journal-title":"VMQ"},{"key":"BF03339790_CR34","first-page":"2648","volume":"91","author":"DE Rimmer","year":"1996","unstructured":"Rimmer D.E., Rawis D.E.: Improper alendronate administration and a case of pill esophagitis. Am. J. Gastroenterol. 91: 2648\u20132649, 1996.","journal-title":"Am. J. Gastroenterol."},{"key":"BF03339790_CR35","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1148\/radiology.206.2.9457190","volume":"206","author":"JM Ryan","year":"1998","unstructured":"Ryan J.M., Kelsey P., Ryan B.M., Mueller P.R.: Alendronate-induced esophagitis: Case report of a recently recognized form of severe esophagitis with esophageal stricture radiographic features. Radiology 206: 389\u2013391, 1998.","journal-title":"Radiology"},{"key":"BF03339790_CR36","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1055\/s-2007-1005544","volume":"28","author":"D Sorrentino","year":"1996","unstructured":"Sorrentino D., Trevisi A., Bernardis V., DeBiase F., Labombarda A., Bartoli E.: Esophageal ulceration due to alendronate. Endoscopy 28: 529, 1996.","journal-title":"Endoscopy"},{"key":"BF03339790_CR37","first-page":"1322","volume":"92","author":"DY Graham","year":"1997","unstructured":"Graham D.Y., Malaty H.M., Goodgame R.: Primary aminobisphosphonates: A new class of gastrotoxic drugs-comparison of alendronate and aspirin. Am. J. Gastroenterol. 92: 1322\u20131325, 1997.","journal-title":"Am. J. Gastroenterol."},{"issue":"Suppl.2","key":"BF03339790_CR38","first-page":"7","volume":"35","author":"FL Lanza","year":"1996","unstructured":"Lanza F.L., Carlson M.R.: The effects of an amino- versus an alkyl-bisphosphonate on the healing of aspirin-induced stomach erosions in healthy subjects. Br. J. Rheumatol. 35 (Suppl. 2): 7, 1996.","journal-title":"Br. J. Rheumatol."},{"key":"BF03339790_CR39","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF01622190","volume":"4","author":"EG Lufkin","year":"1994","unstructured":"Lufkin E.G., Argueta R., Whitaker M.D., Cameron A.L., Wong V.H., Egan K.S., O\u2019Fallon W.M., Riggs B.L.: Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos. Int. 4: 320\u2013322, 1994.","journal-title":"Osteoporos. Int."},{"key":"BF03339790_CR40","volume-title":"Product Characteristics","author":"MerckCo","year":"1995","unstructured":"Merck & Co: Product Characteristics. West Point, Pennsylvania, USA, 1995."},{"key":"BF03339790_CR41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/jbmr.5650100505","volume":"10","author":"P Filipponi","year":"1995","unstructured":"Filipponi P., Pedetti M., Fedeli L., Cini L., Palumbo R., Boldrini S., Massoni C., Cristallini S.: Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J. Bone Miner. Res. 10: 697\u2013703, 1995.","journal-title":"J. Bone Miner. Res."},{"key":"BF03339790_CR42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/8756-3282(93)90240-B","volume":"14","author":"S Giannini","year":"1993","unstructured":"Giannini S., D\u2019Angelo A., Malvasi L., Castrignano R., Pati T., Tronca R., Liberto L., Nobile M., Crepaldi G.: Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 14: 137\u2013141, 1993.","journal-title":"Bone"},{"key":"BF03339790_CR43","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/8756-3282(95)00442-4","volume":"18","author":"P Filipponi","year":"1996","unstructured":"Filipponi P., Cristallini S., Rizzello E., Policani G., Fedeli L., Gregorio F., Boldrini S., Troiani S., Massoni C.: Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. Bone 18: 179\u2013184, 1996.","journal-title":"Bone"},{"key":"BF03339790_CR44","first-page":"107","volume":"11","author":"M Mian","year":"1991","unstructured":"Mian M., Begli\u00e9 F., Caprio A.: Tolerability and safety of clodronate therapy in bone diseases. Int. J. Clin. Pharmacol. Res. 11: 107\u2013114, 1991.","journal-title":"Int. J. Clin. Pharmacol. Res."},{"key":"BF03339790_CR45","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0140-6736(83)91465-4","volume":"1","author":"HM Bounameaux","year":"1983","unstructured":"Bounameaux H.M., Sheifferli J., Montani J.P.: Renal failure associated with intravenous diphosphonates. Lancet 1: 471, 1983.","journal-title":"Lancet"},{"key":"BF03339790_CR46","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/8756-3282(91)90038-K","volume":"12","author":"T Steiniche","year":"1991","unstructured":"Steiniche T., Hasling C., Charles P., Eriksen E.F., Melsen F., Moselkilde L.: The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime. Bone 12: 155\u2013163, 1991.","journal-title":"Bone"},{"key":"BF03339790_CR47","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/jbmr.5650080211","volume":"8","author":"T Storm","year":"1993","unstructured":"Storm T., Steiniche T., Thamsborg G., Melsen F.: Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J. Bone Miner. Res. 8: 199\u2013208, 1993.","journal-title":"J. Bone Miner. Res."},{"key":"BF03339790_CR48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF01622291","volume":"7","author":"JM Pouilles","year":"1997","unstructured":"Pouilles J.M., Tremolliers F., Roux C., Sebert J.L., Alexandre C., Goldberg D., Treves R., Khalifa P., Duntze P., Horlait S., Delmas P.D., Kuntz D.: Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. Osteoporos. Int. 7: 213\u2013218, 1997.","journal-title":"Osteoporos. Int."},{"key":"BF03339790_CR49","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/oxfordjournals.rheumatology.a031451","volume":"36","author":"JH Tobias","year":"1996","unstructured":"Tobias J.H., Dalzell N., Pazianas M., Chambers T.J.: Cyclical etidronate prevents spinal bone loss in early post-menopausal women. Br. J. Rheumatol. 36: 612\u2013613, 1996.","journal-title":"Br. J. Rheumatol."},{"key":"BF03339790_CR50","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0002-9343(97)00019-3","volume":"103","author":"RJM Herd","year":"1997","unstructured":"Herd R.J.M., Balena R., Blake G.M., Ryan P., Fogelman I.: The prevention of early postmenopausal bone loss by cyclical etidronate therapy: A 2-year, double-blind, placebo-controlled study. Am. J. Med. 103: 92\u201399, 1997.","journal-title":"Am. J. Med."},{"key":"BF03339790_CR51","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF01623461","volume":"7","author":"MLM Montessori","year":"1997","unstructured":"Montessori M.L.M., Sheele W.H., Netelenbos J.C., Kerkhoff J.F., Bakker K.: The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. Osteoporos. Int. 7: 52\u201358, 1997.","journal-title":"Osteoporos. Int."},{"key":"BF03339790_CR52","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","volume":"322","author":"T Storm","year":"1990","unstructured":"Storm T., Thamsborg G., Genant H.K., Steiniche T., Soerensen O.H.: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med. 322: 1265\u20131271, 1990.","journal-title":"N. Engl. J. Med."},{"key":"BF03339790_CR53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","volume":"323","author":"NB Watts","year":"1990","unstructured":"Watts N.B., Harris S.T., Genant H.K., Wasnich R.D., Miller P.D., Jackson R.D., Licata A.A., Ross P., Woodson G.C. III, Yanover M., Mysiw J., Kohse L., Rao B., Steiger P., Richmond B., Chesnut C.H. III: Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med. 323: 73\u201379, 1990.","journal-title":"N. Engl. J. Med."},{"key":"BF03339790_CR54","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0002-9343(93)90350-X","volume":"95","author":"ST Harris","year":"1993","unstructured":"Harris S.T., Watts N.B., Jackson R.D., Genant H.K., Wasnich R.D., Ross P., Miller P.D., Licata A.A., Chesnut C.H. III: Four year study on the intermittent cyclical therapy with etidronate in the treatment of postmenopausal osteoporosis: three years of blind therapy followed by one year of open therapy. Am. J. Med. 95: 557\u2013567, 1993.","journal-title":"Am. J. Med."},{"key":"BF03339790_CR55","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0002-9343(97)00278-7","volume":"103","author":"PD Miller","year":"1997","unstructured":"Miller P.D., Watts N.B., Licata A.A., Harris S.T., Genant H.K., Wasnich R.D., Ross P., Jackson R.D., Hoseyni M.S., Schoenfeld S.L., Valent D.J., Chesnut C.H. III: Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment. Am. J. Med. 103: 468\u2013476, 1997.","journal-title":"Am. J. Med."},{"key":"BF03339790_CR56","first-page":"1560","volume":"23","author":"T Storm","year":"1996","unstructured":"Storm T., Kollerup G., Thamsborg G., Genant H.K., Soerensen O.H.: Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. J. Rheumatol. 23: 1560\u20131564, 1996.","journal-title":"J. Rheumatol."},{"key":"BF03339790_CR57","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/rheumatology\/33.4.348","volume":"33","author":"H Mulder","year":"1994","unstructured":"Mulder H., Struys A.: Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br. J. Rheumatol. 33: 348\u2013350, 1994.","journal-title":"Br. J. Rheumatol."},{"key":"BF03339790_CR58","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(94)91932-1","volume":"344","author":"SJ Skingle","year":"1994","unstructured":"Skingle S.J., Crisp A.J.: Increased bone density in patients on steroids with etidronate. Lancet 344: 543\u2013544, 1994.","journal-title":"Lancet"},{"issue":"Suppl.103","key":"BF03339790_CR59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/03009749609103760","volume":"25","author":"RJ Sebaldt","year":"1996","unstructured":"Sebaldt R.J., Adachi J.D., Bensen W.G., Bianchi F., Cividano A., Craig G.L., Cranney A., Kaminska E., Gordon M., Steele M., Goldsmith C.: Intermittent cyclic therapy with etidronate prevents corticosteroid-induced bone loss: two years of follow-up. Scand. J. Rheumatol. 25 (Suppl. 103): 91\u201393, 1996.","journal-title":"Scand. J. Rheumatol."},{"key":"BF03339790_CR60","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJM199708073370603","volume":"337","author":"JD Adachi","year":"1997","unstructured":"Adachi J.D., Bensen W.G., Brown J., Hanley D.A., Hodsman A.B., Josse R., Kendler D.L., Lentle B., Olszynki W., Marie L.G.S., Tenenhouse A., Chines A.A.: Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 337: 382\u2013387, 1997.","journal-title":"N. Engl. J. Med."},{"key":"BF03339790_CR61","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/rheumatology\/37.1.87","volume":"37","author":"T Staa van","year":"1998","unstructured":"van Staa T., Abenhaim L., Cooper C.: Use of cyclical etidronate and prevention of non-vertebral fractures. Br. J Rheumatol. 37: 87\u201394, 1998.","journal-title":"Br. J Rheumatol."},{"key":"BF03339790_CR62","first-page":"281","volume":"17","author":"HR Vries de","year":"1974","unstructured":"de Vries H.R., Bijvoet O.L.M.: Results of prolonged treatment of Paget\u2019s disease of bone with disodium ethane-1-hydroxy-1.1-diphosphonate (EHDP). Neth. J. Med. 17: 281\u2013289, 1974.","journal-title":"Neth. J. Med."},{"key":"BF03339790_CR63","first-page":"2183","volume":"22","author":"T Thomas","year":"1995","unstructured":"Thomas T., Lafage M.H., Alexandre C.: Atypical osteomalacia after 2 year etidronate intermittent cyclical administration in osteoporosis. J. Rheumatol. 22: 2183\u20132185, 1995.","journal-title":"J. Rheumatol."},{"key":"BF03339790_CR64","first-page":"968","volume":"78","author":"SM Ott","year":"1994","unstructured":"Ott S.M., Woodson G.C., Huffer W.E., Miller P.D., Watts N.B.: Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 78: 968\u2013972, 1994.","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl.1","key":"BF03339790_CR65","first-page":"S151","volume":"11","author":"T Storm","year":"1996","unstructured":"Storm T., Soerensen H.A., Thamsborg G., Kollerup G., Soerensen O.H., Steiniche T., Melsen F.: Bone histomorphometric changes after up to seven years of cyclical etidronate treatment. J. Bone. Miner. Res. 11 (Suppl. 1): S151, 1996.","journal-title":"J. Bone. Miner. Res."},{"key":"BF03339790_CR66","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0002-9343(97)00242-8","volume":"103","author":"T Staa van","year":"1997","unstructured":"van Staa T., Abenhaim L., Cooper C.: Upper gastrointestinal adverse events and cyclical etidronate. Am. J. Med. 103: 462\u2013467, 1997.","journal-title":"Am. J. Med."},{"key":"BF03339790_CR67","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/003693309103600207","volume":"36","author":"SJ Gallacher","year":"1991","unstructured":"Gallacher S.J., Boyle I.T., Capell H.A.: Pseudogout associated with the use of cyclical etidronate therapy. Scott. Med. J. 36: 49, 1991.","journal-title":"Scott. Med. J."}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03339790.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03339790\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03339790","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,6]],"date-time":"2019-08-06T18:39:31Z","timestamp":1565116771000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03339790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,8]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,8]]}},"alternative-id":["BF03339790"],"URL":"https:\/\/doi.org\/10.1007\/bf03339790","relation":{},"ISSN":["1594-0667","1720-8319"],"issn-type":[{"value":"1594-0667","type":"print"},{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,8]]}}}